Clinical trials: Falciparum Malaria
Malaria
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
- Trial name
- NCT07036159
- Testing
- RTS,S/AS01E vaccine
- Where
- 2 sites in Rwanda
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults.
- Trial name
- NCT03341754
- Testing
- D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination
In the current study, three experimental approaches aiming at reducing malaria transmission will be tested. The study will cover two transmission season (2019 and 2020) and the interventions will vary by season.
- Trial name
- INDIE-1b (NCT04053907)
- Testing
- Community Case Management, Weekly fever screening and treatment, Monthly malaria screening
- Where
- The Gambia
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Falciparum
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)
The purpose of this study is to assess the gametocytocidal and transmission reducing activity of dihydroartemisinin-piperaquine (DP) with and without various low doses of tafenoquine (TQ; 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg).
- Trial name
- NECTAR2 (NCT04609098)
- Testing
- Dihydroartemisinin/Piperaquine, Tafenoquine 100mg [Arakoda]
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)
The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.
- Trial name
- CHMI-SIKA (NCT02739763)
- Testing
- Plasmodium falciparum sporozoite (PfSPZ)
- Where
- 2 sites in Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar.
- Trial name
- NCT00465257
- Testing
- artesunate + amodiaquine
- Where
- Tanzania
- Volunteers
- 110 people
- Sponsor
- Karolinska University Hospital
Malaria
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 4 sites of the two oral ACTS…
- Trial name
- MEFI_III (NCT04370977)
- Testing
- Coartem™ (Artemether-lumefantrine combination), Winthrop™ (Amodiaquine-artesunate combination)
- Where
- 6 sites in Mozambique
- Volunteers
- 630 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Drug Resistant Malaria Due to Plasmodium Falciparum
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
The antimalarial drugs efficacy and safety study will be conducted in the Clinics and hospital of the Cameroon Development Corporation (CDC) Estates, Tiko Health District, located in a typical forest and rainfall area in the…
- Trial name
- NCT02974348
- Testing
- Arthemeter-lumefantrine, Artesunate mefloquine, Dihydroartemisinin piperaquine
- Where
- Cameroon
- Volunteers
- 300 people
- Sponsor
- University of Bamenda
Malaria
Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy
A) for the treatment of uncomplicated malaria during second and third trimester pregnancy to oral Quinine hydrochloride. The PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is considered as the…
- Trial name
- NCT00495508
- Testing
- Quinine, artemether / lumefantrine
- Where
- Uganda
- Volunteers
- 300 people
- Sponsor
- Epicentre
Malaria
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of the FMP012 combined with AS01B adjuvant system.
- Trial name
- NCT02174978
- Testing
- FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective is to demonstrate the non-inferiority of PCR (Polymerase Chain Reaction) adjusted adequate clinical and parasitological response at Day 28 of Coarsucam versus Coartem, based on the first malaria attack of each…
- Trial name
- SMART-CURE (NCT00699920)
- Testing
- Coarsucam, Coartem
- Where
- Uganda
- Volunteers
- 413 people
- Sponsor
- Sanofi
Malaria
Sanaria™ PfSPZ Challenge Vaccine
This study will randomize 30 healthy adult participants to one of three cohorts comprised of six groups of 5 individuals per group to simultaneously receive PfSPZ Challenge via the ID route.
- Trial name
- NCT01546389
- Testing
- Sanaria™ PfSPZ Vaccine, Chloroquine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine vaccination visits, has been shown to significantly reduce malaria and anemia in two studies in Tanzania.
- Trial name
- NCT00453856
- Testing
- Sulfadoxine Pyrimethamine
- Where
- Gabon
- Volunteers
- 139 people
- Sponsor
- Albert Schweitzer Hospital, Netherlands
Malaria
Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP)…
- Trial name
- NCT05581641
- Testing
- BNT165b1
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Malaria
Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy
Malaria in pregnancy is a major cause of maternal and newborn morbidity and mortality in sub-Saharan Africa]. Effective antimalarial preventive and treatment regimens can significantly reduce malaria-related morbidity and…
- Trial name
- ALN5P (NCT01916954)
- Testing
- 3-day artemether-lumefantrine, 5-day artemether-lumefantrine
- Where
- Republic of the Congo
- Volunteers
- 96 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Pentoxifylline in Children With Malaria
The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and…
- Trial name
- NCT00133393
- Testing
- Pentoxifylline
- Where
- Kenya
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uncomplicated Falciparum Malaria
Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria
Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world.
- Trial name
- ACT (NCT00902811)
- Testing
- AM(FDC), AM(LT), AL
- Where
- 4 sites in Burma
- Volunteers
- 600 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Uncomplicated Plasmodium Falciparum
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported.
- Trial name
- MCHUPF (NCT05829187)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children
Background: The disease malaria can cause very serious health problems. Researchers want to see if malaria affects the way T cells and vaccines work in the body.
- Trial name
- NCT02504918
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)